Shanghai Junshi Biosciences Co., Ltd. Class H (HK:1877) has released an update.
Shanghai Junshi Biosciences Co., Ltd. has announced that the Chinese National Medical Products Administration has accepted their supplemental new drug application for toripalimab combined with bevacizumab, aimed at treating advanced liver cancer. The drug has shown promise in extending survival rates in clinical trials and holds a significant market, with China having a high incidence of liver cancer. Internationally, toripalimab has been making strides, with approvals for treating nasopharyngeal cancer in the US and applications submitted in Europe, Australia, and Singapore for various cancer treatments.
For further insights into HK:1877 stock, check out TipRanks’ Stock Analysis page.
